Polypharmacy and medication use in patients with chronic kidney disease with and without kidney replacement therapy compared to matched controls

被引:30
|
作者
van Oosten, Manon J. M. [1 ]
Logtenberg, Susan J. J. [2 ]
Hemmelder, Marc H. [3 ,4 ]
Leegte, Martijn J. H. [5 ]
Bilo, Henk J. G. [6 ,7 ,8 ,9 ]
Jager, Kitty J. [1 ]
Stel, Vianda S. [1 ]
机构
[1] Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Med Informat, Amsterdam UMC, Amsterdam, Netherlands
[2] Diakonessen Hosp, Dept Internal Med, Utrecht, Netherlands
[3] Maastricht Univ, Dept Internal Med, Div Nephrol, Med Ctr, Maastricht, Netherlands
[4] Maastricht Univ, Cardiovasc Res Inst Maastricht, Maastricht, Netherlands
[5] Nefrovisie Fdn, Dutch Renal Registry, Utrecht, Netherlands
[6] Isala Hosp, Diabet Res Ctr, Zwolle, Netherlands
[7] Isala Hosp, Dept Epidemiol & Stat, Zwolle, Netherlands
[8] Univ Med Ctr Groningen, Dept Internal Med, Groningen, Netherlands
[9] Univ Groningen, Fac Med, Groningen, Netherlands
关键词
CKD; dialysis; health claims data; kidney transplantation; medication use; polypharmacy; AMBULATORY HEMODIALYSIS-PATIENTS; PILL BURDEN; OLDER-ADULTS; EPIDEMIOLOGY; MANAGEMENT; COST;
D O I
10.1093/ckj/sfab120
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. This study aims to examine polypharmacy (PP) prevalence in patients with chronic kidney disease (CKD) Stage G4/G5 and patients with kidney replacement therapy (KRT) compared with matched controls from the general population. Furthermore, we examine risk factors for PP and describe the most commonly dispensed medications. Methods. Dutch health claims data were used to identify three patient groups: CKD Stage G4/G5, dialysis and kidney transplant patients. Each patient was matched to two controls based on age, sex and socio-economic status (SES) score. We differentiated between 'all medication use' and 'chronic medication use'. PP was defined at three levels: use of >= 5 medications (PP), >= 10 medications [excessive PP (EPP)] and >= 15 medications [hyper PP (HPP)]. Results. The PP prevalence for all medication use was 87, 93 and 95% in CKD Stage G4/G5, dialysis and kidney transplant patients, respectively. For chronic medication use, this was 66, 70 and 75%, respectively. PP and comorbidity prevalence were higher in patients than in controls. EPP was 42 times more common in young CKD Stage G4/G5 patients (ages 20-44years) than in controls, while this ratio was 3.8 in patients >= 75years. Older age (64-75 and >= 75years) was a risk factor for PP in CKD Stage G4/G5 and kidney transplant patients. Dialysis patients >= 75years of age had a lower risk of PP compared with their younger counterparts. Additional risk factors in all patients were low SES, diabetes mellitus, vascular disease, hospitalization and an emergency room visit. The most commonly dispensed medications were proton pump inhibitors (PPIs) and statins. [GRAPHICS] . Conclusions. CKD Stage G4/G5 patients and patients on KRT have a high medication burden, far beyond that of individuals from the general population, as a result of their kidney disease and a large burden of comorbidities. A critical approach to medication prescription in general, and of specific medications like PPIs and statins (in the dialysis population), could be a first step towards more appropriate medication use.
引用
收藏
页码:2497 / 2523
页数:27
相关论文
共 50 条
  • [31] Strategies for Reducing Polypharmacy and Other Medication-Related Problems in Chronic Kidney Disease
    Mason, Nancy A.
    Bakus, Jodie L.
    SEMINARS IN DIALYSIS, 2010, 23 (01) : 55 - 61
  • [32] PREDICTING MORTALITY BEFORE RENAL REPLACEMENT THERAPY IN CHRONIC KIDNEY DISEASE PATIENTS
    Lees, Jennifer
    Gillis, Keith
    Jardine, Alan
    Mark, Patrick
    Traynor, Jamie
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [33] EFFECTS OF RENAL REPLACEMENT THERAPY ON FIBROMYALGIA SYNDROME IN PATIENTS WITH CHRONIC KIDNEY DISEASE
    Berber, Ilhami
    Sahin, Idris
    Gorgel, Ahmet
    Cagin, Yasir Furkan
    Bag, Harika Gozukara
    Berber, Nurcan Kirici
    ACTA MEDICA MEDITERRANEA, 2018, 34 (02): : 337 - 343
  • [34] ASSESSMENT OF PHYSICAL ACTIVITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND RENAL REPLACEMENT THERAPY
    Hayhurst, William S. G.
    Ahmed, Aimun
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [35] Extrapulmonary tuberculosis in patients with chronic kidney disease receiving renal replacement therapy
    Johnson, Emma
    Shah, Krishna
    Rahman, Ananna
    Mccafferty, Kieran
    Tiberi, Simon
    Kunst, Heinke
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [36] Unadjusted medication dose in patients with chronic kidney disease
    Rashidi, Arash
    SOUTHERN MEDICAL JOURNAL, 2008, 101 (08) : 777 - 778
  • [37] Symptom burden in patients with chronic kidney disease not requiring renal replacement therapy
    Brown, Stephanie A.
    Tyrer, Freya C.
    Clarke, Amy L.
    Lloyd-Davies, Laetitia H.
    Stein, Andrew G.
    Tarrant, Carolyn
    Burton, James O.
    Smith, Alice C.
    CLINICAL KIDNEY JOURNAL, 2017, 10 (06) : 788 - 796
  • [38] Assessment of physical activity in patients with chronic kidney disease and renal replacement therapy
    Hayhurst, William S. G.
    Ahmed, Aimun
    SPRINGERPLUS, 2015, 4
  • [39] Medication adherence among patients with chronic kidney disease
    Khan, S
    Giomi, A
    Sim, M
    Ghayal, P
    CIRCULATION, 2004, 109 (20) : E286 - E286
  • [40] Effects of testosterone replacement therapy on quality of life in patients with chronic Kidney disease
    Park, Min Gu
    Lee, Jeong Woo
    Yeo, Jeong Kyun
    Lee, Hae Won
    Kim, Jae Heon
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 : 249 - 249